Outsourcing in Clinical Trials Nordics 201417-18 September 2014, Copenhagen, Denmark
The OCT team would like to thank you for making the 2013 launch event such a huge success.
With healthcare innovation and growth being considered a top priority for the Nordic region, clinical trials are regarded as a key aspect of delivery innovation, with governments incentivising and rewarding such efforts. One of the key considerations for the Nordics is the need for collaboration. Furthermore, with the increased rewards for innovation, the industry is looking to increase R&D activity, which in turn means there will be considerable development within clinical trials. Against this backdrop, OCT Nordics will allow companies from within this Nordic-specific hub to come together and discuss proven strategies to improve and create partnerships within clinical trials and medical devices.
Alongside the biopharmaceutical outsourcing sessions, we will also include unique medical device-specific sessions in a separate stream covering: medical device outsourcing, patient recruitment and new regulations (e.g. MDD). This year’s event will have more of an operational focus and bring together senior industry representatives to discuss the latest challenges within clinical outsourcing and medical device-related challenges such as: improved vendor communication strategies, vendor sourcing/selection, budgeting and contracting, oversight and management, patient recruitment, risk-based monitoring and feasibility plans.
Outsourcing in Clinical Trials Nordics 2014 promises to be a highly engaging meeting and will present a unique platform for discussion alongside thought-sharing on innovative strategies within outsourcing models in this ever-growing region.
The Outsourcing Clinical Trial series is growing every year. View the full list of upcoming events to make sure you don’t miss any news. The list of websites will be updated as soon as new events are live so check back regularly
Primary delegates for this event are those with responsibility for clinical outsourcing in biotech and pharma companies within the Nordic region.
Testimonials from other events in our Outsourcing in Clinical Trials Series
Outsourcing in Clinical Trials Nordics boasts a fantastic exhibition of clinical service providers and industry specialists. Our exhibition area is already filling up due to the fantastic launch event which took place this year. If you have a service or solution you would like to promote at this event, please use the details below to make contact with our commercial team.
Cubist Pharmaceuticals has filed a new drug application (NDA) with the US Food and Drug Administration (FDA) for its investigational antibiotic, ceftolozane/tazobactam for the treatment of complicated urinary tract infections (cUTI) and complicated i…
Pfizer has released top-line results from two major Phase III trials from the Oral treatment Psoriasis Trials (OPT) Programme, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), of tofacitinib, the first in a new class of medicines, to treat pa…
US-based VentiRx Pharmaceuticals has announced the completion of patient enrollment in GOG-3003, a Phase II study of VTX-2337 in combination with pegylated liposomal doxorubicin (PLD) in patients with recurrent or persistent epithelial ovarian, fallo…
US-based biopharmaceutical firm Questcor Pharmaceuticals has reported results from an investigator-initiated clinical trial evaluating the dosing and effectiveness of HP Acthar Gel (repository corticotropin) in 20 patients with nephrotic syndrome due…
US-based biopharmaceutical firm AbbVie has started a global Phase III clinical trial of an investigational oral poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor 'veliparib (ABT-888)' in patients with previously untreated locally …
Sweden-based Aprea, a Karolinska Development portfolio company, has started dosing patients in the Phase I/II clinical trial of APR-246 in combination with chemotherapy to treat ovarian cancer.